MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.26 (+1.76%)

Stability Price

Overvalued by 90.55%

Company Metrics

  • 13.83 P/E
  • 15.11 P/S
  • 3.83 P/B
  • -1.91 EPS
  • -5.97% Cash ROIC
  • 8.05 Cash Ratio
  • 0 / 0% Dividend
  • 693,476.00 Avg. Vol.
  • 803.41M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Motley Fool - Feb 19, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial ... - GlobeNewswire (press release)
Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc. (Fed. Cir ...
Patent Docs - Aug 10, 2012
Momento Pharmaceuticals The case involved a District Court grant of a preliminary injunction to Momenta in litigation between two ANDA filers.
Momenta Pharmaceuticals, Inc. Pushes Forward
Motley Fool - Nov 5, 2014
At this point, earnings calls for Momenta Pharmaceuticals (NASDAQ: MNTA ) are more an opportunity to update investors than to report revenue and earnings.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results ... - Seeking Alpha (registration)
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results - MarketWatch
Momenta Pharmaceuticals Inc. (MNTA): New Analyst Report from Zacks Equity ...
Nasdaq - Feb 4, 2015
Cambridge, MA-based Momenta Pharmaceuticals, Inc. is a biotechnology company focused on designing products on the basis of a complex systems analysis platform, analyzing data to assess the biological function of these products and developing ...
Momenta Pharmaceuticals Inc. v. Amphastar Pharmaceuticals, Inc.: "The Rest of ...
Patent Docs - Aug 14, 2012
Chief Judge Rader Judge Rader wrote a vigorous dissent to the panel majority's opinion in Momenta v. Amphastar, disagreeing with the panel majority's interpretation that the "safe harbor" embodied in 35 U.S.
Momenta Pharmaceuticals Inc. Stock Downgraded (MNTA) - Mar 4, 2014
MOMENTA PHARMACEUTICALS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Momenta Pharmaceuticals Inc. (MNTA) is Trading Lower on Unusual Volume for ... - Mar 20, 2015
Momenta Pharmaceuticals Inc. ($MNTA) experienced unusually high volume on Mar. 20, as the stock lost 0.06% to a closing price of $15.46.
Momenta Pharmaceuticals Hits New 12-Month High at $15.98 (MNTA) - The Legacy
Momenta Pharmaceuticals Reaches New 12-Month High at $15.98 (MNTA) - WKRB News
Earnings Preview: MGM Resorts International, Momenta Pharmaceuticals, Inc ...
Schaeffers Research (blog) - Feb 13, 2015
Elsewhere, short-term calls are popular in Momenta Pharmaceuticals, Inc.'s options pits, per its Schaeffer's call/put open interest ratio (SOIR) of 0.19, which sits in the 12th percentile of its annual range.
Momenta Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of ...
Insurance News Net - Feb 26, 2015
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Insider Trades for February, 25th (B, BLL, DTE, GS, HSIC, MNTA, MPWR, MSA ... - WKRB News
Insider Trades for February, 23rd (ARW, AWAY, BXP, CHE, COLM, CRL, CRMT ... - sleekmoney
Zacks Long Term Rating Update on Momenta Pharmaceuticals, Inc.
Stafford Daily - Feb 24, 2015
As much as 5 analysts have advised buy on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) with an average broker rating of 1.8.